Specification of COVID-19 Vaccines for the Purpose of the Maritime Border Order
Pursuant to section 5(3)(b) of the COVID-19 Public Health Response Act 2020, I, Dr Ashley Bloomfield, Director-General of Health, declare that the doses of each COVID-19 vaccine or combination of COVID-19 vaccines specified in this notice are required for a person to be “vaccinated” for the purpose of clause 12 of the COVID-19 Public Health Response (Maritime Border) Order (No 2) 2020 (“Order”). A combination of vaccine doses will meet the definition where this is the accepted schedule in the place of vaccination.
For the purposes of clause 12 of the Order, vaccinated means being vaccinated against COVID-19 with at least one of the following complete vaccination courses (meaning the combination of COVID-19 vaccine and number of doses in each line):
|
|
Manufacturer |
Vaccine name |
Other names (including research name) |
Dose(s) required |
|
1. |
Bharat Biotech |
Covaxin |
BBV152 |
2 |
|
2. |
Janssen (Johnson & Johnson) |
Janssen |
Ad26.COV2.S1 JNJ-78436735 |
1 |
|
3. |
Moderna |
Spikevax |
mRNA-1273 |
2 |
|
4. |
Novavax |
Nuvaxovid |
NVX-CoV2373 |
2 |
|
5. |
Oxford/AstraZeneca |
Vaxzevria |
AZD1222 ChAdOx1 nCoV-19 |
2 |
|
6. |
Pfizer/BioNTech |
Comirnaty |
BNT162b2 Tozinameran |
2 |
|
7. |
Serum Institute of India (AstraZeneca) |
Covishield |
AZD1222 |
2 |
|
8. |
Serum Institute of India (Novavax) |
Covovax |
|
2 |
|
9. |
Sinopharm (Beijing) |
BBIBP-CorV |
Covilo Also LIBP, CCIBP, CDIBP, CNBG, BIBP |
2 |
|
10. |
Sinovac |
CoronaVac |
PiCoVacc |
2 |
|
11. |
CanSinoBIO |
Convidecia |
PakVac Ad5-nCoV |
1 |
|
12. |
Anhui Zhifei Longcom |
Zifivax |
ZF2001 ZF-UZ-VAC-2001 RBD-Dimer |
2 |
|
13. |
Bagheiat-allah University of Medical Sciences |
Noora |
|
3 |
|
14. |
Biological E Limited |
Corbevax |
BECOV2D |
2 |
|
15. |
Center for Genetic Engineering and Biotechnology (CIGB) |
Abdala
|
CIGB-66 |
2 |
|
16. |
Chumakov Centre |
KoviVac |
|
2 |
|
17. |
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI) |
EpiVacCorona |
VECTOR
|
2 |
|
18. |
Federal Budgetary Research Institution State Research Center of Virology and Biotechnology (FBRI) |
EpiVacCorona-N |
Aurora-CoV
|
2 |
|
19. |
Gamaleya Research Institute of Epidemiology and Microbiology |
Sputnik Light |
|
1 |
|
20. |
Gamaleya Research Institute of Epidemiology and Microbiology |
Sputnik V |
Gam-COVID-Vac |
2 |
|
21. |
Gamaleya Research Institute of Epidemiology and Microbiology |
Gam-COVID-Vac |
Sputnik rAd5 |
2 (Nasal spray) |
|
22. |
Health Institutes of Turkey |
Turkovac |
ERUCOV-VAC |
2 |
|
23. |
Instituto Finlay de Vacunas Cuba |
Soberana 02 |
FINLAY-FR-2 Pasteurcovac |
2 |
|
24. |
Instituto Finlay de Vacunas Cuba |
Soberana Plus |
FINLAY-FR-1A |
Only as a 3rd dose after 2 doses of Soberana 02 |
|
25. |
Kazakhstan Research Institute for Biological Safety Problems |
QazVac |
QazCovid-in RIBSPm |
2 |
|
26. |
Medicago Inc. |
COVIFENZ |
coVLP |
2 |
|
27. |
Medigen Vaccine Biologics Corporation |
MVC COVID-19 vaccine |
MVC-COV1901 |
2 |
|
28. |
Shenzhen Kangtai Biological Products, Minhai Biotechnology Co (Beijing) |
KCONVAC |
KconecaVac Minhai COVID-19 vaccine BIOKANGTAI |
2 |
|
29. |
National Vaccine and Serum Institute (China) |
Recombinant SARS-CoV-2 Vaccine (CHO Cell) |
NVSI-06-08 |
3 |
|
30. |
Organization of Defensive Innovation and Research (Iran) |
FAKHRAVAC |
MIVAC |
2 |
|
31. |
Razi Vaccine and Serum Research Institute (Iran) |
Razi Cov Pars |
|
3 |
|
32. |
Shifa Pharmed Industrial Co (Iran) |
COVIran Barekat |
BIV1-CovIran COVIran Barakat COVIran Barkat |
2 |
|
33. |
Sinopharm (Wuhan) |
WIBP-CorV |
Inactivated (Vero Cells) |
2 |
|
34. |
Takeda (Japan)/ Novavax |
TAK-019 |
(Novavax formulation) |
2 |
|
35. |
Takeda (Japan)/ Moderna |
TAK-919 |
(Moderna formulation) |
2 |
|
36. |
Valneva SE/ Dynavax Technologies |
VLA2001 |
VLA2101 |
2 |
|
37. |
Vaxine/CinnaGen Co. (Australia) |
SpikoGen |
COVAX-19 |
2 |
|
38. |
Zydus Cadila (Cadila Healthcare) |
ZyCoV-D |
|
3 |
This notice comes into effect at 11.59pm on 31 July 2022.
Dated at Wellington this 26th day of July 2022.
Dr ASHLEY BLOOMFIELD, Te Tumu Whakarae mō te Hauora, Director-General of Health.